Clinical Trial Update: S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

SWOG trial S0351 evaluating CNTO 328 for unresectable or metastatic kidney cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CNTO 328

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Kidney Cancer | Phase 2 | Status: WITHDRAWN